

Sustainability Accounting Standards Board (SASB)

Our Annual Report on Form 10-K (filed with the U.S. SEC), or our Annual Report, and our Directors' Report and Consolidated Financial Statements (filed with the Irish Companies Registration Office), or our Directors' Report, include metrics aligned with the Medical Equipment & Supplies industry specific Sustainability Accounting Standards Board (SASB) standards. We seek to provide investors with useful, relevant, and meaningful sustainability information and have selected metrics under the SASB Standards. The table below summarizes our fiscal year 2024 responses and the location of the disclosure. Our reporting against the SASB standard is a voluntary disclosure. More information on our ESG function and our process for continuously monitoring and tracking our policies and activities in the areas of ethical business practices, energy and environmental conservation, employees and human capital management, and quality can be found in our Annual Report and our Directors' Report. Nothing contained on or accessible through this website shall be deemed to be part of our Annual Report and our Directors' Report.

Topic	Accounting Metric	Code	STERIS FY24 Response	Annual Report Section	Directors' Report Section
Product Safety	Number of recalls issued, total units recalled.	HC-MS-250a.1	STERIS had no Class I recalls in fiscal 2024, 2023 or 2022.	Item 1. Business - Quality	Directors' Report - Quality
	Total FDA MedWatch safety alert products.	HC-MS-250a.2	STERIS had zero products listed in the FDA's MedWatch Safety Alerts for Human Medical Products database.	Item 1. Business - Quality	Directors' Report - Quality
	Number of FDA enforcement actions taken.	HC-MS-250a.4	In fiscal 2024, STERIS did not receive any warning letters, seizures, or consent decrees.	Item 1. Business - Quality	Directors' Report - Quality
Ethical Marketing	Total monetary losses as a result of false marketing claims.	HC-MC-270a.1	In fiscal 2024, STERIS incurred no monetary losses as a result of legal proceedings associated with false marketing claims.	Item 1. Business – Ethical Business Practices – Managing Compliance and Ethics	Directors' Report - Ethical Business Practices – Managing Compliance and Ethics
	Description of code of ethics governing promotion of off-label use of products.	HC-MS-270a.2	The STERIS Code of Business Conduct covers ethical marketing and off-label promotion.	Item 1. Business – Ethical Business Practices – Managing Compliance and Ethics	Directors' Report - Ethical Business Practices – Managing Compliance and Ethics
Business Ethics	Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption.	HC-MS-510a.1	In 2024, STERIS incurred no monetary losses as a result of legal proceedings associated with bribery or corruption.	Item 1. Business – Ethical Business Practices – Anti-Bribery and Anti-Corruption	Directors' Report - Ethical Business Practices – Anti-Bribery and Anti-Corruption
	Description of code of ethics governing interactions with health care professionals.	HC-MS-510a.2	STERIS has adopted and requires compliance with the AdvaMed Code.	Item 1. Business – Ethical Business Practices – Managing Compliance and Ethics	Directors' Report - Ethical Business Practices – Managing Compliance and Ethics